Pre-Emptive Analgesia in Dental Implant Surgery
Pain, Postoperative

About this trial
This is an interventional treatment trial for Pain, Postoperative
Eligibility Criteria
Inclusion Criteria:
- Adult patients 18 years of age and under 65 years of age
- ASA Type I & II
- Single tooth edentulous site requiring dental implant placement without any additional bone or soft tissue augmentation at the time of implant placement
- Patients not requiring use of any form of sedation for dental implant surgery (nitrous, oral or IV sedation)
Exclusion Criteria:
- Hypersensitivity to NSAIDs, salicylates, or microcrystalline cellulose NF (Avicel PH 105)
- Liver disease
- Renal disease
- Hypertension and taking angiotensin-converting-enzyme inhibitors and/or diuretics
- Significant respiratory conditions including acute or severe asthma.
- Cardiovascular disease that will prevent the patient from going through the surgical procedure or consuming the required medications: cardiac disease, cardiomyopathy, cardiac arrhythmias, coronary heart disease, acute MI, angina, history of MI, coronary artery bypass grafting (CABG), Aspirin intake, peripheral vascular disease, cerebral vascular disease (stroke, TIA)
- Gastrointestinal disease including irritable bowel disease and gastric ulcers
- Hematological diseases (coagulopathy, hemophilia or thrombocytopenia)
- Pregnancy/lactation at the time of surgery
- Heavy smoking (>10 cigarettes per day)
- Diabetes
- Allergies or intolerance to ibuprofen, opioids, and local anesthetic (lidocaine and bupivacaine)
- History of recreational drug abuse
- History of heavy alcohol use. Substance Abuse and Mental Health Services Administration (SAMSHA)30 defines heavy alcohol use as binge drinking on 5 or more days in the past month. SAMSHA defines binge drinking as 5 or more alcoholic drinks for males or 4 or more alcoholic drinks for females on the same occasion (i.e., at the same time or within a couple of hours of each other) on at least 1 day in the past month.
- Patients currently taking prescription pain medications or have taken over-the-counter pain medications within 4 days of surgery.
- Patients with drug-drug or drug-disease state interactions
- Other significant medical conditions (not reported above) that are likely to prevent the patient from going through the surgical procedure or consuming the required medications.
Sites / Locations
- Univerity of Iowa College of Dentsitry Dental Clinics
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Local Anesthetic Group 1
Local Anesthetic Control
Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
Group 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.